JC07 B PCT/PTO 0 8 NOV 2001 #3 7/009574

Filing Date

If Appropriate

Form PTO-1449

Examiner

Initial

PTO/SB/08 (2-92)

INFORMATION DISCLOSURE CITATION **BY APPLICANT**

Date

Z70538-1P US APPLICANT

DOCKET NUMBER

Sheet 1 of 1
US APPLICATION NUMBER
Not Known 10/009,574

AstraZeneca AB

Reinstein et al.

Subclass

Patent and Trademark Office, U.S. Department of Commerce

FILING DATE

U.S. PATENT DOCUMENTS

Name

GROUP ART UNIT

(Use several sheets if necessary)

Document Number

4-22-02

Class

Not Known 1624

	Dogwood Nivert		EIGN PATENT DOCUME		Oh =1	~	1-4:
	Document Number	Public Date	Country	Class	Subclass	Yes	slation No
BC	WO 97/32037	4 Sept 1997	PCT WIPO				
BC	WO 98/04289	5 Feb 1998	PCT WIPO				
BC	EP 0 830 864 A1	25 March 1998	Europe				
BC	WO 00/54764	21 Sept 2000	PET WIPO			٠.	
	OTH	ER DOCUMENTS	(Including Author, Title, Date	e, Pertinent Pag	es, Etc.)		
	PCT/GB00/01875 International Search Report						
8C	S. J. Nasr. NASR Psychiatric Services PC, Michigan City, USA; XP-001009548 Resoluction of Rapid Weigh						
	Gain on Olanzapine after substitution with Quetiapine, 2000.						
BC	J. B. Robertson jr., L Treosti, K.D. Walker, Center for Family Psychiatry, Tennessee, USA; XP001010838						
	Successful use of high dos quetiapine in a patient with a psychiatric disorder resistant to olanzapine, 200						
BC	Lalith K. Misra, DVM, PhD, DO, et al; University of South Dakota School of Medicine; XP-000901163						
			chotic; June, 1998; pp 189				
BC	Michael J. Reinstein, et al; Clinical Research Dept, Forest Foundation Inc., Chicago, Illinois, USA;						
	XP001009552 Efect of Clozapine-Quetiapine Combination Therapy on Weight and Glycaemic Control Preliminary Findings; Clin Drug Invest 1999 Aug: 18(2); pp 99 - 104						
					J. Antineveho	tion (Colle	horativo
BC	Herbert Y. Meltzer, M.D. et al.; XP-001009550 Adverse Effects of the Atypical Antipsychotics (Collaborative Working Group on Clinical Trial Evaluations); J. Clin. Psychiatry 1998;59[suppl 12]: pp17-22						
	Josee E. Leysen et al; XP-001009585 Receptor interactions of new antipsychotics: relation to						
BC	pharmacodynamic and clinical effects; International Journal of Psychiatry in Clinical Practice 1998 Volume 2						
	pp S3 – S17						
							
	 				-		